ERBB2 and breast carcinoma: A phase I clinical trial (NCT04040686) is currently ongoing to evaluate the safety, dosimetry and efficacy of 99mTc labeled anti-HER2 nanobodies in diagnostic imaging of HER2 in breast cancer patients.